Harmony Biosciences Holdings, Inc. HRMY Pitolisants — License Agreement Upfront Fee Paid
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harmony Biosciences Holdings, Inc. in its filing.
Tagged under the XBRL concept hrmy:LicenseAgreementUpfrontFeePaid.
The source filing: Harmony Biosciences Holdings, Inc.’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 8:16 AM EST
- Fiscal year
- FY2026
- Accession
- 0001104659-26-018859
On January 11, 2026, the Company entered into a license agreement with a third party, which includes an exclusive license to additional intellectual property that will expand the patent estate of the Company, as well as a co-exclusive license, with which the Company intends to develop a new formulation of pitolisant in broad CNS indications outside of sleep/wake. Under the license agreement, the Company paid an upfront license fee of $15,000 and will also be obligated to pay up to $10,000 upon achievement of certain development milestones, as well as low single-digit royalties on net sales of pitolisant based products.
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Harmony Biosciences Holdings, Inc.'s pitolisants — license agreement upfront fee paid?
- Harmony Biosciences Holdings, Inc. (HRMY) reported pitolisants — license agreement upfront fee paid of $15M in Q1 2026.
- What does pitolisants — license agreement upfront fee paid mean?
- This represents the total initial consideration paid at the inception of a licensing agreement to obtain rights to a pharmaceutical product or technology. It reflects the immediate cash outlay required to initiate the partnership and secure the asset for the company's portfolio. This metric is a key component of the total cost of acquisition for external innovation.
Ask your AI about Harmony Biosciences Holdings, Inc.'s pitolisants — license agreement upfront fee paid.
Connect your AI assistant and compare it to peers, right in your chat.
